UNSPSC 51111656: Tegafur

This classification denotes a thymidylate synthase inhibitor and pyrimidine antagonist with the molecular formula C8H9FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1548R74NSZ, chemically known as 2,4(1h,3h)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (r)- but generally known as tegafur, which bears US NIH Compound Identifier 5386. European Medicines Agency schedules Tegafur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10870MIG.

UNSPSC 51111656 Tegafur, a Commodity code, designates a single pharmaceutical product line — the anticancer drug tegafur, typically acquired by state and local health agencies as part of formulary procurement, pharmacy benefit management, or specialized treatment protocols. State and local governments buy tegafur through health and human services departments, Medicaid programs, correctional health systems, and hospital networks that serve covered populations. The recent solicitation activity under this code reflects a shift toward direct-to-manufacturer contracting models that bypass traditional pharmacy benefit managers and wholesalers, with state procurement offices testing vendor capacity to negotiate net pricing and implement outcomes-based agreements rather than relying on rebate structures common in conventional pharmaceutical supply chains.

The Texas Health and Human Services Commission issued Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to gather vendor capabilities and market intelligence on direct-to-manufacturer prescription programs. The RFI seeks vendors experienced with direct contracting for self-insured employers and health plans in both private and government sectors within the prior two years, flexibility to negotiate on net pricing models without rebates, and capacity to implement value-based or outcomes-based agreements. This preliminary information-gathering phase signals Texas HHS Commission's intent to develop detailed procurement specifications and pricing models for subsequent formal solicitations once the state completes its market assessment. No award values, budget ranges, set-aside designations, or formal evaluation criteria are specified at this RFI stage.